SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.61-0.6%Nov 6 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (3177)3/23/2001 4:48:04 PM
From: keokalani'nui  Read Replies (2) of 52153
 
I have never seen discussion of IMCL here or generally on SI. To be sure, it would be hard to improve on the Yahoo thread--but it is sooo worshipful.

And I have learned there is one investment criteria to be paid attention to: where there is no sophisticated sponsorship from this crowd, one should well be sure of oneself or be prepared for pain.

With its colorectal (and pancreatic? H&N?) results coming up for presentation and dissection at asco, would anyone have any cautionary or recklessly positive thoughts about C225? I can certainly see there is a fat relative valuation, but if it works, things could still be quite yummy.

If my situation is important to get a response, I am long IMCL at lower prices. But it would hurt dearly to be immunexed.

As ever, grateful for the welcoming spirit that lives here.

Wilder
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News